公开(公告)号：EP4190323A1

公开(公告)日：2023-06-07

申请号：EP21856175.1

申请日：2021-08-10

申请人： Oncocross Co., Ltd.

发明人： KIM, Yi-Rang

IPC分类号： A61K31/197 ,  A61K31/138 ,  A61K31/522 ,  A61P25/28 ,  A23L33/10

摘要： The present invention relates to a pharmaceutical composition comprising calcium pantothenate, or calcium pantothenate and dimenhydrinate as active ingredients for prevention and treatment of myopathy. According to the present disclosure, calcium pantothenate upregulates the expression of MHC, myogenin 4-EBP, and p70S6K to promote myoblast differentiation and myogenesis, thereby prolonging the duration of life in amyotrophic lateral sclerosis patients and promoting the growth of MSC in Duchenne muscular dystrophy mice. Such effects are synergistically increased upon combined treatment with dimenhydrinate. Thus, they can be advantageously used for preventing or treating myopathy.

公开(公告)号：EP4306110A1

公开(公告)日：2024-01-17

申请号：EP22767339.9

申请日：2022-02-07

申请人： Oncocross Co., Ltd.

发明人： KIM, Yi-Rang

IPC分类号： A61K31/44 ,  A61K31/352 ,  A61P3/00 ,  A61P1/16 ,  A23L33/10

摘要： The present invention relates to a composition for the treatment of metabolic diseases, containing torsemide and cromolyn. According to the present invention, if torsemide and cromolyn are used in combination, compared to when cromolyn alone is used, weight is reduced, insulin resistance is reduced and liver fat accumulation is remarkably reduced in a NASH animal model, and thus the present invention can be effectively used in the prevention or treatment of metabolic diseases including diabetes, obesity, insulin resistance and metabolic liver diseases.

公开(公告)号：EP3607949A1

公开(公告)日：2020-02-12

申请号：EP19789574.1

申请日：2019-04-17

申请人： Oncocross Co., Ltd.

发明人： KIM, Yi-Rang ,  CHOI, Jin-Woo

IPC分类号： A61K31/522 ,  A61K31/437 ,  A61K31/197 ,  A61P21/00 ,  A23L33/10

摘要： The present invention relates to a pharmaceutical composition for prevention or treatment of a muscular disease, the composition comprising dimenhydrinate, harmol and/or calcium pantothenate as active ingredients. Application of dimenhydrinate, harmol, and calcium pantothenate individually has an effect of promoting myoblast proliferation and differentiation. In particular, the combination thereof has the effect of synergistically increasing the effect of promoting myoblast proliferation and differentiation. Thus, dimenhydrinate, harmol and/or calcium pantothenate may be usefully used alone or in combination for the prevention or treatment of muscular diseases, in particular sarcopenia.